Summary:
A Phase 1, Open-Label, Pharmacokinetics Study of a Single Intravenous Infusion of Pamrevlumab in Healthy Asian (Japanese and Chinese) and Non-Asian Subjects
Criteria:- Be of Chinese or Japanese Hertiage
- Currently not using any prescription or over-the-counter medications or vitamins
- Be available for 5 consecutive inpatient nights in a hospital setting
Qualified Participants May Receive:
Compensation for participating up to $2,800 over the study length (90 days)